Joint venture contract with Zydus Cadila to be amended for the production of active pharmaceutical ingredients (API) Transfer of chemical production from facilities in Singen (Germany) and Linz (Austria) to India until 2011 Singen and Linz will focus on pharmaceutical production Nycomed and Cadila Healthcare have signed a letter agreement with the intent to amend their existing joint venture agreement to include the chemical production of active pharmaceutical ingredients (APIs) by the joint venture company Zydus Nycomed in India......

Total net turnover increases by 3.0% to € 3,497.4 million 31.0% increase in adjusted EBITDA Instanyl™ filed for European approval Own Pantoprazole generic as response to US at-risk launch Major progress in US out-licensing strategy Acquisition of Bradley Pharmaceuticals successfully closed The financial results reported in this press release are related to Nycomed S......

Nycomed creates a leading specialty pharmaceutical player in dermatology Enhanced platform for in-licensing and co-promotion of dermatology products Combined US dermatology sales of $450 million Today, Nycomed successfully completed the acquisition of Bradley Pharmaceuticals, a company focused on niche therapeutic markets in the United States......

Legal counsel to be integral part of Executive Committee Nycomed’s Board of Directors has appointed Michael Kuner Executive Vice President Legal. He joins the company’s Executive Committee with immediate effect......

-Own presence in Venezuela to further enhance strong Latin American presence -Nycomed strategy to participate in high-growth markets and offer licensing opportunities to partners Nycomed is about to establish its own marketing and sales organisation in Venezuela......

Own generic of Pantoprazole introduced to US market Move in response to at-risk launch of generic Pantoprazole in the United States Nycomed and Wyeth remain convinced of valididity and enforcability of their patent and continue to pursue litigation Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), today announced the U......

Sepracor acquires exclusive development, marketing and commercialisation rights to the Ciclesonide franchise in the United States Ciclesonide is the active ingredient in the ALVESCO® Inhalation Aerosol for asthma and the Omnaris™ Nasal Spray for allergic rhinitis ALVESCO® and Omnaris™ are FDA-approved and are on track to be launched in 2008 Agreement is in alignment with Nycomed’s strategy to cooperate with the best partners for its key brands in the United States Partnership between Nycomed and Sepracor provides a good strategic fit for both companies Nycomed has granted Sepracor, Inc......

ALVESCO® (ciclesonide) Inhalation Aerosol approved by FDA for the maintenance and prophylactic treatment of asthma in patients 12 years of age and older ALVESCO® will be commercialised by U......

Surgical patch TachoSil® planned to enter US market with partner Baxter Important milestone for Nycomed’s partnership strategy for the US market Nycomed grants Baxter International Inc......

Marketing authorisation application filed for Europe through the Centralised Procedure Treatment aimed at opioid tolerant patients with cancer experiencing breakthrough pain Strengthening the Nycomed pain control portfolio Nycomed filed a marketing authorisation application with the European Medicines Agency (EMEA) for an intranasal fentanyl spray in Europe on December 7, 2007......

Net turnover increases by 4.9% for the first nine months of 2007 29.4% increase in adjusted EBITDA Strong margin growth and reduced spending Integration of Altana Pharma ahead of plan with positive effect on business opportunities and spending levels Bid for Bradley Pharmaceuticals Teduglutide in-licensed The financial results reported in this press release are related to Nycomed S......

Acquisition will add to the branded dermatologic line as a growth driver for the future Integration of Bradley will provide an enhanced platform for in-licensing and co-promotion of dermatology products Bradley Pharmaceuticals will be integrated with the PharmaDerm and Fougera divisions of Nycomed’s US specialty business Combined sales of Nycomed US and Bradley amount to approximately €320 million/$450 million on an annualised basis Nycomed today announced the entry into a definitive agreement to acquire Bradley Pharmaceuticals, Inc......

Nycomed acquires exclusive rights outside North America GATTEX™ matches Nycomed’s capabilities in gastroenterology Total upfront payments of $35 million and potential for more than $150 million milestone payments Nycomed and NPS Pharmaceuticals, Inc......

Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the United States District Court for the District of New Jersey denied Nycomed’s and Wyeth’s motion for a preliminary injunction against Teva Pharmaceuticals USA, Inc......

The financial results reported in this press release are related to Nycomed S.C.A. SICAR and comprises all of the Nycomed Group’s operations including the ALTANA Pharma activities acquired in December 2006......

Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the United States District Court for the District of New Jersey has taken the matter of Wyeth and Nycomed’s motion for a preliminary injunction against Teva Pharmaceuticals USA, Inc......

Nycomed and its partner NPS Pharmaceuticals announced today that they have entered an agreement expanding and amending rights and responsibilities under the Preotact® (full-length parathyroid hormone [PTH 1-84]) license originally entered into in 2004......